CD274 and non-small cell lung carcinoma: A multi-center cohort study has revealed that TMB-high outperformed PD-L1 in predicting the response and survival outcomes of NSCLC patients who received PD-L1 inhibitors that were associated with higher infiltrating CD8+ T cells and upregulations of several immune-related signaling pathways (Ricciuti et al., 2022).